VALNEVA news, videos and press releases
For more news please use our advanced search feature.
VALNEVA - More news...
VALNEVA - More news...
- Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
- Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
- Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
- Valneva Hosts Investor Day in New York City
- Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
- Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
- VALNEVA - Declaration of shares and voting rights: August 31, 2024
- Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
- Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
- VALNEVA - Declaration of shares and voting rights: July 31, 2024
- VALNEVA - Declaration of shares and voting rights: May 31, 2024
- Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
- Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
- Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Declaration of voting rights - Valneva SE, March 2024
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
- Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
- Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
- Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
- VALNEVA: Declaration of shares and voting rights - January 31, 2024
- Valneva Announces Sale of Priority Review Voucher for $103 Million
- Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
- Valneva Provides Updated 2023 Financial Guidance
- Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
- Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
- EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment
- VALNEVA Declaration of shares and voting rights: October 31, 2023
- Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
- VALNEVA - Declaration of shares and voting rights: September 30, 2023
